News

The rejection follows the company’s previously dismissed proposal to install wind turbines at the facility. The company, which has accepted the decision, is working with Marine Scotland to

As per the agreement, the new JV will be named Amgen-Beta Pharmaceuticals and Zhejiang Beta Pharma will own 51% while Amgen will own the remaining 49% interest in

Marina Biotech research and development executive vice president Richard Ho said the SMARTICLES delivery technology is advancing into another clinical development effort. "With the initiation of this trial,

MOR208’s efficacy in patients with relapsed or refractory NHL will be assessed in the open-label, multicentre trial. MorphoSys chief development officer Dr. Arndt Schottelius said MOR208 cancer program

The investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2) completed the open-label, pioneer portion of the trial. Lexicon president and chief executive

DKSH provides contract sales services in both private clinics and trade channel for the antibiotic product line of GlaxoSmithKline. GlaxoSmithKline (Hong Kong) vice president and general manager Sally

The first interleukin-1 beta inhibitor is the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection. Novartis Pharmaceuticals development global head Timothy Wright

A statistically significant increase in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy compared to placebo was not observed. The safety data were steady

The approval by Therapeutic Goods Administration (TGA) in Australia has triggered a $4m milestone payment to Curis, which is even eligible for sales based royalties of Roche’s Erivedge